What is Advanced Bifurcation Systems?
Founded in 2006, Advanced Bifurcation Systems operates at the intersection of medical device innovation and cardiovascular health. The company specializes in disruptive technology designed specifically for left main heart disease, providing clinicians with advanced tools to stent coronary arteries at critical branch points. By offering a paradigm shift in how interventional cardiologists approach complex anatomy, the firm has established a unique market position. Its technology addresses a high-acuity segment of the healthcare market, moving beyond traditional stenting methods to improve patient outcomes in high-risk procedures. The company's trajectory from its 2020 Series A round to its current debt-based financing reflects a mature approach to scaling its clinical footprint and operational infrastructure.
How much funding has Advanced Bifurcation Systems raised?
Advanced Bifurcation Systems has raised a total of $31.8M across 2 funding rounds:
Series A
$11M
Debt
$20.8M
Series A (2020): $11M with participation from Cedars-Sinai
Debt (2025): $20.8M, investors not publicly disclosed
Key Investors in Advanced Bifurcation Systems
Cedars-Sinai
A world-renowned non-profit academic medical center based in Los Angeles, specializing in complex clinical programs and advanced medical research.
Undisclosed Investor
An undisclosed institutional partner participating in the recent debt financing round to support the company's strategic growth objectives.
What's next for Advanced Bifurcation Systems?
With the recent influx of capital, Advanced Bifurcation Systems is positioned to accelerate its commercialization efforts and deepen its clinical research initiatives. The strategic deployment of these funds will likely focus on expanding the reach of its ABS platform, potentially targeting broader adoption within major academic medical centers and specialized heart institutes. As the company navigates the complexities of the interventional cardiology landscape, the focus remains on long-term value creation through technological differentiation. Future growth will likely hinge on the firm's ability to translate its clinical efficacy into standard-of-care status, leveraging its established relationships with top-tier medical institutions to drive market penetration and sustain its competitive advantage in the cardiovascular device sector.
See full Advanced Bifurcation Systems company page
